For a pediatric patient (33 kg) with methicillin‑susceptible Staphylococcus aureus (MSSA) osteomyelitis, after increasing vancomycin from 500 mg every 6 hours to 750 mg three times daily, what is the optimal steady‑state trough concentration to target when area‑under‑the‑curve (AUC) cannot be calculated?

Optimal Vancomycin Trough Target for Pediatric MSSA Osteomyelitis

For your 33 kg pediatric patient with MSSA osteomyelitis, target a trough concentration of 15-20 mg/L when AUC monitoring is unavailable. This higher target is specifically recommended for complicated infections including osteomyelitis, even though the organism is MSSA rather than MRSA 1.

Rationale for the 15-20 mg/L Target

The IDSA/ASHP/SIDP consensus guidelines explicitly state that for complicated infections such as osteomyelitis, trough concentrations of 15-20 mg/L are recommended to achieve adequate tissue penetration and improve clinical outcomes 1. This recommendation applies regardless of whether the pathogen is MSSA or MRSA, as the pharmacodynamic principles for bone penetration remain the same.

Why Not Lower Targets?

• Minimum 10 mg/L is insufficient: While troughs ≥10 mg/L prevent resistance development 1, this baseline target was designed for less complicated infections
• Osteomyelitis requires higher exposure: Bone penetration is challenging, and the infection site demands sustained therapeutic concentrations to achieve clinical cure
• Your initial trough of 11.9 mg/L was subtherapeutic for osteomyelitis, correctly prompting your dose increase

Dosing Considerations for Your Patient

Your dose escalation from 500 mg q6h (approximately 60 mg/kg/day) to 750 mg TDS (approximately 68 mg/kg/day) is reasonable, though the TDS schedule is less optimal than q6h dosing:

• Pediatric patients typically require 60-80 mg/kg/day to achieve target troughs of 15-20 mg/L 2, 3
• Consider returning to q6h dosing at approximately 550-600 mg q6h rather than TDS to maintain more consistent serum concentrations
• The FDA label recommends 10 mg/kg q6h for pediatric patients, but this consistently underachieves therapeutic targets in real-world practice 4

Monitoring Strategy

Since AUC calculation is unavailable:

• Obtain steady-state trough before the 4th dose after any dosing change 1
• Target 15-20 mg/L specifically - do not accept lower values for osteomyelitis
• Monitor renal function closely when targeting higher troughs, though nephrotoxicity risk remains acceptable in this range 1
• Recent pediatric data suggest troughs up to approximately 15 mg/L (corresponding to AUC ~530) balance efficacy and safety 5

Critical Caveats

The 2009 IDSA guidelines explicitly excluded pediatric data 1, but subsequent pediatric research confirms that children require higher mg/kg doses than adults to achieve equivalent exposures 2, 3, 6. Your patient's age and weight place them in a cohort that typically needs 65-79 mg/kg/day to reach therapeutic targets 3.

MSSA vs MRSA distinction: While your patient has MSSA (not MRSA), the infection site (osteomyelitis) drives the need for higher vancomycin exposure, not the organism's methicillin susceptibility. Consider whether a beta-lactam (such as cefazolin or nafcillin) might be superior for MSSA osteomyelitis, as these agents typically achieve better bone penetration and have more favorable safety profiles 7.

Practical Algorithm

1. Immediate: Target trough 15-20 mg/L with your current increased dose
2. Consider: Switching to q6h dosing (approximately 550 mg q6h) for more stable levels
3. Monitor: Trough before 4th dose after any change, then weekly if stable
4. Reassess: If trough remains <15 mg/L, increase to 70-75 mg/kg/day
5. Alternative: Strongly consider switching to an anti-staphylococcal penicillin (nafcillin/oxacillin) or cefazolin for MSSA, which may provide superior outcomes with less toxicity risk